asiapacif
region
span
one
third
globe
circumfer
contain
half
world
popul
highli
divers
cultur
polit
econom
dimens
impact
vaccin
develop
implement
region
includ
china
japan
second
third
largest
nation
economi
global
time
also
encompass
global
allianc
vaccin
immun
gavi
elig
countri
region
divers
experienc
breakneck
econom
develop
stage
vaccin
innov
product
consumpt
repres
along
paradox
overlap
relianc
aid
vaccin
program
countri
also
vaccin
export
india
indonesia
philippin
vietnam
gavielig
countri
produc
bacil
vaccin
oral
polio
vaccin
measl
vaccin
unicef
india
grow
sourc
diphtheriatetanuspertussishaemophilu
influenza
type
b
dtphib
contain
combin
vaccin
export
supplier
novel
meningococc
group
conjug
vaccin
africa
china
meanwhil
export
novel
live
attenu
hepat
vaccin
india
pandem
vaccin
chile
season
influenza
hepat
b
japanes
enceph
je
rabi
meningococc
typhoid
polysaccharid
vaccin
develop
develop
countri
broad
incom
rang
within
countri
result
larg
popul
segment
suffici
mean
pay
vaccin
outofpocket
even
among
countri
otherwis
qualifi
econom
gavi
fund
eg
india
substanti
number
famili
avail
vaccin
cover
nation
expand
programm
immun
epi
result
twotier
system
vaccin
parallel
publicpriv
dichotomi
health
care
deliveri
gener
practition
serv
expatri
famili
gener
follow
current
us
european
australian
vaccin
recommend
modif
schedul
percept
valu
vaccin
risk
also
rang
wide
region
within
individu
countri
larg
enthusiast
accept
even
demand
addit
routin
vaccin
eg
je
vaccin
southern
southeast
asia
degre
skeptic
equal
deepli
wide
held
antivaccin
sentiment
europ
unit
state
within
last
year
japan
discontinu
product
use
combin
measl
mump
rubella
vaccin
routin
childhood
influenza
je
vaccin
program
larg
owe
vaccinerel
advers
event
public
percept
occurr
similarli
korea
parent
object
routin
je
vaccin
case
vaccinerel
acut
dissemin
encephalopathi
suspect
natur
acquir
case
je
global
spread
inform
thimeros
content
childhood
vaccin
activ
parent
concern
among
middleclass
famili
develop
countri
elsewher
mosaic
tri
describ
common
theme
highlight
repres
approach
uniqu
issu
hold
wider
interest
cover
elsewher
volum
review
specif
vaccin
region
concern
eg
pandem
influenza
je
vaccin
vaccin
topic
common
develop
countri
eg
initi
surround
inject
safeti
hepat
b
measl
neonat
tetanu
elimin
polio
erad
concentr
instead
aspect
vaccin
develop
implement
organ
step
vaccin
develop
approv
product
recommend
deliveri
also
restrict
focu
childhood
vaccin
vaccin
select
countri
region
japan
acknowledg
innov
sever
vaccin
use
intern
includ
acellular
pertussi
live
attenu
varicella
vaccin
novel
vaccin
develop
japan
china
india
australia
vietnam
regionspecif
need
tabl
includ
vaccin
je
hemorrhag
fever
renal
syndrom
hfr
russian
springsumm
enceph
kyasanur
forest
diseas
cholera
sever
acut
respiratori
syndrom
sar
q
fever
addit
novel
attenu
strain
measl
mump
hepat
rotaviru
intranas
deliv
pandem
viru
deriv
product
distribut
princip
within
region
addit
novel
vaccin
hepat
e
enteroviru
develop
potenti
broader
use
intern
indic
region
transit
provid
fillfinish
manufactur
capac
fullfledg
particip
biotechnolog
research
clinic
develop
five
je
vaccin
develop
licens
asian
countri
wide
use
firstgener
inactiv
suckl
mous
brain
smb
deriv
vaccin
replac
rapidli
econom
disadvantag
countri
chines
develop
manufactur
live
attenu
vaccin
sa
strain
grown
primari
babi
hamster
kidney
phk
cell
higher
incom
countri
vero
cellderiv
inactiv
vaccin
licens
japan
china
unit
state
australia
immun
asiapacif
region
hfr
widespread
rodentborn
bunyavir
zoonosi
asia
pantrop
infect
promin
capillari
hemorrhag
interstiti
nephriti
casefat
ratio
last
decad
caus
annual
case
republ
korea
case
china
although
diseas
well
known
part
russia
asia
sporad
occasion
epidem
diseas
among
farmer
soldier
other
expos
campestr
sylvat
habitat
larg
unknown
west
thousand
militari
case
death
occur
korean
war
diseas
describ
korean
hemorrhag
fever
administ
outbreak
control
mani
chines
provinc
licens
vaccin
use
smb
primari
gerbil
babi
hamster
kidney
cell
vero
cell
line
substrat
shown
efficaci
tabl
chinesemanufactur
babi
gerbil
kidney
cell
gkc
deriv
vaccin
provid
seroconvers
immunofluoresc
neutral
assay
respect
three
vaccin
dose
day
random
control
threearm
trial
vaccin
subject
receiv
three
primari
dose
booster
dose
year
later
hfr
case
observ
control
subject
compar
none
vaccine
case
unvaccin
subject
followup
protect
efficaci
lower
confid
limit
p
cumul
bionomi
probabl
efficaci
primari
seri
alon
shown
year
administr
primari
seri
booster
dose
case
occur
three
group
respect
among
case
control
unvaccin
group
caus
hantaan
viru
seoul
viru
viru
indetermin
serotyp
thu
monoval
vaccin
protect
diseas
caus
hantaan
seoul
viral
serotyp
vaccinerel
seriou
advers
event
report
trial
mild
local
system
reaction
report
subject
bival
gkcderiv
vaccin
immunogen
induc
neutral
antibodi
hantaan
seoul
virus
subject
geometr
mean
titer
gmt
respect
bival
vero
cellderiv
vaccin
immunogen
rang
bival
gkcderiv
vaccin
licens
recent
efficaci
phk
smb
vaccin
similar
nonrandom
trial
hfr
case
found
recipi
phk
cellderiv
vaccin
compar
unvaccin
subject
reduct
smb
vaccin
rate
per
vs
per
vaccine
unvaccin
subject
respect
reduct
nonsever
advers
reaction
observ
recipi
phk
cellderiv
smbderiv
vaccin
recipi
korea
monoval
hantaan
viru
strain
smbderiv
vaccin
also
licens
base
immunogen
challeng
data
mice
accompani
controversi
field
trial
yugoslavia
vaccin
strain
rok
isol
human
case
serial
passag
brain
suckl
mice
purifi
formalin
inactiv
follow
procedur
product
je
vaccin
immunogen
twodos
primari
seri
small
number
human
subject
variabl
plaqu
reduct
neutral
test
igg
enzymelink
immunosorb
assay
importantli
one
studi
plaqu
reduct
neutral
test
titer
persist
subject
year
primari
seri
booster
immun
led
rise
subject
postboost
gmt
lower
titer
second
primari
dose
serolog
correl
protect
establish
observ
suggest
need
booster
dose
month
maintain
immun
vaccin
welltoler
princip
local
reactogen
casecontrol
studi
show
doserel
trend
potenti
indic
effect
increas
confid
interv
ci
one
dose
ci
two
dose
ci
three
dose
studi
evalu
protect
averag
month
incid
hfr
china
korea
declin
last
year
introduct
vaccin
probabl
importantli
rural
econom
develop
lead
improv
cement
hous
grain
harvest
storag
practic
rapid
urban
result
reduc
exposur
rodent
reservoir
trend
evid
rapidli
develop
area
southeastern
china
like
continu
region
lead
diminish
diseas
incid
potenti
discontinu
routin
vaccin
endem
provinc
two
similar
live
attenu
vaccin
base
strain
licens
china
attenu
passag
new
monkey
kidney
cell
c
follow
five
passag
cell
substrat
c
viru
subsequ
adapt
grow
cultur
human
diploid
fibroblast
carri
addit
four
passag
temperatur
one
dose
vaccin
contain
hepat
viru
hav
titer
log
tcid
administ
subcutan
oral
administr
fail
induc
antibodi
thu
attenu
viru
transmiss
person
person
genet
stabil
demonstr
nucleotid
ident
two
passag
marmoset
eight
passag
cell
cultur
c
singl
dose
vaccineinduc
igg
enzymelink
immunosorb
assay
antibodi
peak
month
result
seroconvers
vaccine
gmt
miuml
specif
antibodi
declin
gradual
persist
protect
level
miuml
vaccine
year
later
field
trial
individu
random
children
year
old
disclos
hav
case
vaccine
case
control
subject
protect
efficaci
p
lower
confid
limit
cumul
bionomi
probabl
studi
period
time
number
acut
hepat
b
case
similar
popul
one
vaccin
group
two
control
group
cluster
random
trial
among
school
children
year
old
disclos
case
hav
vaccine
case
control
subject
acut
hepat
b
detect
vaccine
control
subject
vaccin
welltoler
vaccinerel
sever
advers
event
report
frequenc
elev
alanin
aminotransferas
level
similar
vaccin
control
group
matern
antibodi
interf
live
attenu
vaccin
young
infant
studi
among
infant
vaccin
month
age
whose
mother
antihav
posit
seroposit
year
age
compar
whose
mother
detect
antihav
second
dose
log
tcid
given
month
first
dose
low
hav
concentr
vaccin
log
tcid
induc
good
booster
respons
antihav
seroposit
increas
month
month
gmt
miuml
compar
respons
induc
two
dose
intern
licens
inactiv
hav
vaccin
havrix
glaxosmithklin
howev
singl
dose
vaccin
recommend
subject
age
outbreak
among
school
children
vaccin
administ
part
student
bodi
peak
outbreak
day
immun
case
detect
vaccine
compar
case
unvaccin
children
thu
given
low
attack
rate
unvaccin
group
remain
proven
whether
vaccin
provid
postexposur
protect
major
measl
vaccin
deriv
edmonston
strain
two
attenu
vaccin
base
wildtyp
virus
isol
later
time
shanghai
strain
develop
china
detail
avail
chapter
toward
fulfil
nation
goal
selfsuffici
vaccin
nation
institut
hygien
epidemiolog
vietnam
develop
oral
bival
kill
wholecel
cholera
vaccin
produc
distribut
vabiotech
compani
vaccin
biolog
product
hanoi
anoth
oral
bival
vaccin
produc
india
detail
found
chapter
new
zealand
outbreak
meningococc
diseas
due
specif
clone
group
b
meningococcu
caus
total
case
report
meningococc
diseas
case
period
due
singl
por
subtyp
feasibl
commiss
tailormad
outer
membran
vesicl
vaccin
control
outbreak
detail
avail
chapter
relat
enterovirus
caus
princip
selflimit
febril
herpangina
syndrom
handfootandmouth
diseas
occur
sporad
cosmopolitan
distribut
includ
unit
state
sinc
emerg
major
season
epidem
eastern
southeast
asia
lead
million
case
thousand
complic
case
necessit
hospit
hundr
death
outbreak
china
although
epidem
greatest
impact
china
taiwan
singapor
malaysia
outbreak
also
concern
japan
korea
thailand
hong
kong
australia
impact
due
high
attack
rate
result
daycar
kindergarten
closur
case
hospit
neurolog
cardiopulmonari
complic
asept
mening
acut
flaccid
paralysi
pulmonari
edema
arrhythmia
cardiac
failur
shock
occur
incid
high
per
children
younger
year
casefat
ratio
rang
depend
definit
sever
case
brainstem
infect
result
autonom
dysregul
implic
pathogenesi
pulmonari
edema
system
inflammatori
respons
lead
increas
pulmonari
vascular
permeabl
direct
injuri
myocardium
rule
contribut
caus
sever
psychomotor
damag
frequent
complic
recoveri
central
hypoventil
motor
paralysi
sever
cognit
impair
development
delay
occur
half
children
younger
year
experienc
cardiopulmonari
complic
hospit
rate
death
disabl
would
signific
parent
anywher
singl
child
polici
china
similar
famili
structur
taiwan
world
lowest
birth
rate
singapor
focus
even
public
pressur
govern
control
diseas
rapid
vaccin
develop
prioriti
regulatori
approv
analog
process
pandem
influenza
vaccin
advanc
market
commit
discuss
countri
least
five
vaccin
candid
institut
compani
china
taiwan
singapor
advanc
stage
develop
field
efficaci
trial
complet
expedit
licensur
expect
base
convent
inactiv
whole
virion
antigen
without
alum
model
inactiv
polioviru
vaccin
bottleneck
identif
candid
strain
provid
adequ
yield
stabil
product
also
crossneutr
strain
genotyp
proof
principl
confirm
vaccin
rhesu
monkey
challeng
intraven
respiratori
rout
pup
vaccin
pregnant
mice
challeng
birth
recogn
anim
model
establish
poor
suscept
older
mice
although
one
viru
serotyp
recogn
viru
classifi
genet
genotyp
subtyp
strain
circul
almost
exclus
china
b
subtyp
circul
predominantli
taiwan
southeast
asia
regulatori
polit
consider
may
constrain
use
strain
base
local
molecular
epidemiolog
pattern
chinesedevelop
vaccin
approv
state
food
drug
administr
escherichia
coli
express
viruslik
particl
compos
recombin
purifi
peptid
correspond
aa
hepat
e
viru
hev
viral
capsid
protein
aa
encod
three
dose
genotyp
vaccin
contain
g
alumadjuv
antigen
given
month
led
uniform
seroconvers
young
adult
pivot
efficaci
field
trial
conduct
jointli
vaccin
develop
provinci
cdc
case
clinic
ill
alt
elev
confirm
hev
igm
plu
polymeras
chain
reaction
posit
detect
hevvaccin
healthi
adult
subject
case
due
genotyp
strain
confirm
crossgenotyp
protect
observ
hepat
bvaccin
control
subject
follow
month
efficaci
ci
howev
sensit
case
definit
two
three
hev
marker
hevrna
igm
igg
antihev
antibodi
confirm
case
vaccin
efficaci
vaccin
welltoler
vaccinerel
sever
advers
event
report
trial
pregnant
women
infant
peopl
chronic
hepat
plan
detail
avail
chapter
implicit
region
progress
toward
novel
vaccin
develop
matur
capac
conduct
clinic
trial
improv
toward
robust
regulatori
process
capac
includ
pharmacovigil
system
addit
multin
compani
increasingli
turn
countri
asia
conduct
clinic
trial
lower
cost
streamlin
regulatori
approv
clinic
trial
applic
intern
contract
research
organ
oper
mani
countri
grow
local
infrastructur
conduct
clinic
trial
complianc
intern
confer
harmonis
technic
requir
registr
pharmaceut
human
use
good
clinic
practic
standard
lead
clinic
research
conduct
region
unlik
europ
asian
countri
unifi
central
regulatori
approv
process
region
public
health
presenc
latin
america
pan
american
health
organ
lead
region
vaccin
program
also
provid
central
purchas
certain
qualifi
vaccin
howev
associ
southeast
asian
nation
asean
includ
bruneidarussalam
cambodia
indonesia
lao
pdr
malaysia
myanmar
philippin
singapor
thailand
vietnam
initi
effort
subregion
regulatori
harmon
scheme
reduc
differ
technic
requir
regulatori
procedur
pharmaceut
harmon
initi
undertaken
associ
free
trade
agreement
remov
barrier
region
commerc
pharmaceut
product
work
group
form
aim
harmon
pharmaceut
regul
member
countri
elimin
technic
barrier
trade
without
compromis
product
qualiti
efficaci
safeti
eventu
subregion
mutual
recognit
procedur
similar
european
union
envis
importantli
local
clinic
trial
requir
registr
abbrevi
pathway
specifi
asean
common
technic
dossier
vaccin
approv
licens
elsewher
certain
benchmark
regulatori
agenc
result
certif
pharmaceut
product
contrast
nation
regulatori
author
nra
china
india
japan
korea
taiwan
requir
local
clinic
trial
registr
unlik
us
food
drug
administr
requir
certain
proport
us
studi
subject
new
submiss
rational
local
clinic
data
expand
safeti
immunogen
databas
previou
file
concern
local
racial
ethnic
environment
differ
could
affect
respons
local
popul
genet
base
differ
drug
pharmacokinet
pharmacodynam
well
diseas
risk
increasingli
recogn
includ
immun
respons
vaccin
studi
antibodi
respons
pneumococc
conjug
vaccin
asia
exampl
found
higher
prevaccin
postvaccin
antibodi
titer
among
philippin
taiwanes
infant
compar
european
histor
control
subject
basi
differ
may
earlier
exposur
life
pneumococci
crossreact
antigen
region
differ
host
microbiom
possibl
genet
restrict
respons
observ
hepat
b
measl
vaccinia
rubella
hib
antigen
discount
becom
understood
newli
defin
field
vaccinom
descript
individu
regulatori
requir
clinic
trial
applic
new
product
approv
beyond
scope
chapter
see
previou
edit
detail
introduct
govern
greater
role
vaccin
manufactur
region
elsewher
although
devolut
toward
privat
stateown
enterpris
soe
ie
governmentown
corpor
occur
eg
commonwealth
serum
laboratori
australia
privat
six
major
govern
vaccin
institut
china
oper
soe
tabl
although
grow
number
privat
manufactur
emerg
especi
china
india
countri
nation
local
govern
manufactur
continu
import
sourc
certain
vaccin
domest
need
eg
govern
pharmaceut
offic
thailand
research
institut
tropic
medicin
philippin
biofarma
indonesia
nation
institut
hygien
epidemiolog
vietnam
central
research
institut
local
govern
institut
india
thai
gpo
viet
nihe
also
export
je
vaccin
sri
lanka
andra
pradesh
india
respect
facil
also
fill
distribut
bulk
vaccin
suppli
intern
manufactur
sever
privat
soe
manufactur
region
member
develop
countri
vaccin
manufactur
network
consortium
seek
identifi
develop
solut
common
challeng
face
manufactur
develop
countri
number
manufactur
oper
practic
procedur
prequalifi
produc
certain
vaccin
unicef
purchas
eg
dtp
hepat
b
measl
vaccin
allow
export
vaccin
countri
region
world
health
organ
prequalif
requir
manufactur
plant
must
satisfi
gmp
inspect
addit
nation
notif
advers
event
follow
immun
captur
analyz
satisfactorili
last
requir
princip
impedi
prequalif
product
countri
work
toward
clearer
definit
basic
requir
blueprint
pharmacovigil
system
develop
countri
grow
extent
multin
compani
acquir
partner
local
compani
region
result
manufactur
standard
regul
improv
toward
meet
intern
specif
tabl
list
region
princip
vaccin
manufactur
licens
product
rapid
turnov
privat
compani
claim
impli
list
comprehens
vaccin
manufactur
elsewher
refil
distribut
local
manufactur
list
countri
region
divid
broadli
countri
singl
nation
schedul
countri
basic
schedul
free
epi
vaccin
supplement
recommend
profession
organ
nation
pediatr
societi
addit
antigen
paid
outofpocket
countri
first
group
includ
one
hand
mainli
develop
countri
offer
basic
epi
schedul
countri
like
australia
new
zealand
taiwan
provid
univers
vaccin
program
includ
array
antigen
combin
vaccin
parallel
european
us
schedul
continu
introduct
new
frequent
expens
vaccin
ongo
tension
vaccin
recommend
fund
entiti
must
weigh
rel
valu
innov
prevent
therapeut
health
expenditur
countri
region
total
per
capita
expenditur
health
care
may
less
cost
full
cours
expens
novel
vaccin
hand
nation
schedul
region
comprehens
includ
human
papillomaviru
vaccin
australia
influenza
varicella
vaccin
eg
korea
taiwan
time
hib
vaccin
still
recommend
jurisdict
high
per
capita
incom
hong
kong
singapor
degre
seemingli
paradox
recommend
rel
high
incom
countri
region
reflect
differ
social
expect
person
respons
health
care
purchas
see
subsequ
text
shown
tabl
nation
schedul
provid
option
recommend
antigen
avail
inexpens
dtwphibhepb
combin
vaccin
highlight
enough
made
possibl
introduct
hib
antigen
schedul
econom
disadvantag
countri
otherwis
would
adopt
monoval
vaccin
shown
tabl
mani
countri
govern
tender
choos
specif
manufactur
product
specif
combin
recommend
nation
schedul
addit
antigen
provincialspecif
recommend
address
region
differ
risk
eg
routin
group
ac
meningococc
vaccin
china
je
vaccin
sarawak
malaysia
torr
strait
australia
rabi
vaccin
preexposur
area
philippin
countri
public
health
author
draw
extern
advisor
help
formul
nation
vaccin
recommend
advisori
committe
immun
practic
acip
taiwan
korea
expert
committe
immun
singapor
chines
expert
committe
epi
hong
kong
scientif
committe
vaccin
prevent
diseas
immun
committe
indonesian
pediatr
societi
australian
technic
advisori
group
immun
exampl
medic
advisori
group
japan
process
revamp
vaccin
approv
recommend
process
soon
establish
aciplik
bodi
malaysian
pediatr
associ
pediatr
societi
thailand
advis
respect
ministri
acip
formul
nation
recommend
india
indonesia
pakistan
philippin
thailand
nation
schedul
includ
basic
epi
antigen
academ
pediatr
societi
nongovernment
coalit
organ
promulg
schedul
includ
broader
rang
vaccin
reflect
close
recommend
unit
state
europ
australia
schedul
bodi
shown
respect
nation
epi
schedul
tabl
vaccin
deliv
vari
proport
public
privat
channel
depend
mainli
local
incom
level
access
privat
practition
gener
vaccin
nation
schedul
avail
cost
primari
health
center
equival
eg
puskesma
indonesia
polyclin
govern
hospit
clinic
singapor
malaysia
thailand
villag
counti
level
center
diseas
control
china
villag
commun
vietnam
public
health
center
clinic
india
japan
gener
practition
gp
offic
australia
rule
cost
vaccin
reimburs
avail
free
public
clinic
even
affluent
countri
famili
may
attend
govern
clinic
hospit
obtain
routin
vaccin
wellchild
care
eg
singapor
famili
obtain
vaccin
govern
system
polyclin
hospit
howev
avoid
long
wait
time
rotat
staff
public
clinic
mani
famili
opt
obtain
otherwis
free
vaccin
privat
pay
outofpocket
pediatr
gp
privat
clinic
addit
newer
vaccin
may
delay
introduct
nation
reimburs
scheme
common
parent
pay
vaccin
outofpocket
exampl
korea
children
seoul
vaccin
privat
purchas
might
expect
distribut
incom
proport
children
vaccin
govern
primari
health
center
higher
rural
area
overal
approxim
children
thailand
malaysia
vaccin
public
channel
china
vaccin
control
cdc
therefor
nearli
chines
children
receiv
free
epi
well
payabl
option
vaccin
eg
hib
varicella
rotaviru
other
public
clinic
coverag
epi
vaccin
select
countri
summar
figur
econom
growth
develop
asia
secular
trend
popul
structur
evolut
health
care
system
forc
inevit
chang
variou
aspect
immun
region
asyet
unforese
way
popul
asia
region
age
shift
toward
structur
larger
proport
adult
elderli
person
birth
cohort
asia
decreas
slightli
million
popul
children
year
old
hold
nearli
constant
number
proport
adult
year
increas
dramat
number
peopl
older
year
nearli
doubl
million
demograph
crossov
point
adult
year
children
younger
year
reach
europ
occur
within
anoth
gener
asia
figur
except
almost
univers
epi
program
tetanu
toxoid
vaccin
pregnant
women
adult
vaccin
view
mainli
context
travel
group
meningococc
vaccin
hajj
tropic
asia
influenza
vaccin
appropri
travel
temper
locat
howev
sar
pandem
outbreak
region
threat
influenza
focus
attent
routin
season
influenza
vaccin
first
time
mani
countri
begin
elderli
popul
result
high
pediatr
vaccin
coverag
develop
countri
region
je
becom
almost
exclus
diseas
adult
older
year
reflect
intrins
biolog
suscept
older
adult
neurotrop
flavivirus
suggest
futur
need
adult
vaccin
hepat
interestingli
princip
risk
cohort
young
adult
rais
era
econom
develop
improv
sanit
therefor
lack
natur
immun
born
routin
childhood
vaccin
implement
catchup
program
fill
demograph
hole
recogn
adult
vaccin
recommend
countri
china
adult
measl
vaccin
discuss
case
occur
annual
last
year
adult
older
year
infant
receiv
first
vaccin
dose
respect
proport
econom
develop
eastern
provinc
grow
awar
adult
vaccin
reflect
increas
number
countri
adult
vaccin
recommend
tabl
mcv
two
popul
trend
influenc
demand
vaccin
channel
deliveri
urban
incom
dispar
urbandwel
popul
asia
project
increas
almost
billion
person
billion
billion
rural
popul
declin
slightli
urban
crowd
like
affect
transmiss
pattern
certain
persontoperson
transmit
diseas
even
infect
acquir
environment
sourc
dengu
exampl
transmit
mosquito
vector
preval
urban
environ
alreadi
great
need
dengu
vaccin
almost
certainli
increas
growth
urban
center
grow
size
number
larg
citi
may
increas
transmiss
certain
infect
deliveri
vaccin
health
care
gener
better
organ
citi
rural
area
specif
intervent
need
ensur
exist
dispar
access
health
care
urban
rural
dweller
widen
associ
urban
increas
incom
gap
mani
countri
health
arena
translat
twotier
system
health
care
includ
prevent
medicin
vaccin
regard
mani
public
good
provid
govern
servic
mention
access
increas
number
new
vaccin
like
stratifi
incom
level
abil
pay
govern
must
choos
among
increasingli
costli
vaccin
health
intervent
shown
tabl
pediatr
societi
number
countri
promulg
recommend
emul
us
acip
like
schedul
aim
practition
serv
privatepay
famili
diverg
increasingli
nation
epi
schedul
benefit
major
children
countri
public
govern
respond
increas
dispar
perceiv
basic
medic
servic
remain
seen
come
year
novel
vaccin
like
develop
asia
licens
first
asia
region
develop
world
intern
market
trend
accompani
need
strengthen
regulatori
agenc
region
recogn
nra
revis
harmon
guidelin
procedur
intern
standard
enforc
procedur
consist
predict
manner
improv
time
introduct
region
vaccin
develop
intern
import
complianc
intern
standard
requir
region
manufactur
hope
licens
local
develop
vaccin
broadli
mani
countri
still
reli
certif
pharmaceut
product
consider
invest
infrastructur
train
need
nra
provid
full
regulatori
review
new
applic
chines
manufactur
current
export
limit
number
vaccin
mainli
african
latin
american
countri
horizon
undoubtedli
expand
similarli
nonconform
intern
intellectu
properti
convent
obstacl
introduc
intern
develop
product
countri
region
govern
local
manufactur
may
find
take
stricter
view
develop
novel
vaccin
specif
area
regulatori
control
need
particular
attent
strengthen
nation
control
laboratori
mani
countri
lack
laboratori
capac
test
sampl
lot
releas
manufactur
test
technolog
chang
rapidli
keep
new
procedur
purchas
need
equip
ongo
challeng
continu
support
also
need
produc
work
quantiti
refer
standard
valid
new
assay
staff
train
profici
test
resourc
unavail
mani
countri
establish
maintain
fulli
function
nation
control
laboratori
region
network
propos
approach
share
expertis
divid
workload
time
standard
method
criteria
field
surveil
advers
event
follow
immun
anoth
area
pharmacovigil
requir
strengthen
mani
countri
regulatori
oversight
clinic
trial
human
subject
protect
area
grow
pressur
improv
multin
compani
increas
number
clinic
trial
asian
countri
reduc
cost
obtain
local
registr
product
activ
serv
import
role
strengthen
complianc
good
clinic
practic
mani
group
conduct
trial
region
limit
experi
precept
procedur
countri
region
interest
establish
enforc
clear
guidelin
host
increas
number
trial
also
manufactur
futur
sponsor
new
product
account
intern
uphold
recogn
standard
